Taysha Gene Therapies Inc... (TSHA)
NASDAQ: TSHA
· Real-Time Price · USD
2.38
-0.11 (-4.42%)
At close: Jun 24, 2025, 3:59 PM
2.39
0.42%
After-hours: Jun 24, 2025, 07:45 PM EDT
-4.42% (1D)
| Bid | 2.35 |
| Market Cap | 622.44M |
| Revenue (ttm) | 7.22M |
| Net Income (ttm) | -86.77M |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -7 |
| Forward PE | -6.74 |
| Analyst | Buy |
| Ask | 2.6 |
| Volume | 2,268,378 |
| Avg. Volume (20D) | 3,861,261 |
| Open | 2.52 |
| Previous Close | 2.49 |
| Day's Range | 2.37 - 2.55 |
| 52-Week Range | 1.05 - 3.31 |
| Beta | 1.02 |
About TSHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TSHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TSHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Taysha Gene Therapies Inc. is scheduled to release its earnings on Aug 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+12.7%
Taysha Gene Therapies shares are trading higher af...
Unlock content with
Pro Subscription
3 weeks ago
-6.51%
Taysha Gene Therapies shares are trading higher. The company announced a proposed public offering of common stock.
3 weeks ago · seekingalpha.com
Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP AmendmentsTaysha Gene Therapies, Inc. achieved positive updated data from Part A of the phase 1/2 REVEAL study using TSHA-102 to treat patients with Rett Syndrome. Alignment gained with FDA on IND amendments to...
1 month ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptTaysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relat...
